NantBioScience, a wholly-owned subsidiary of NantWorks, focuses on creating targeted oncology drugs that match treatments to the molecular profile of each patient’s tumor rather than its anatomical origin. Leveraging next-generation sequencing, targeted proteomics, and large-scale supercomputing, the firm aims to replace traditional ‘trial-and-error’ clinical trial design with data-driven predictability. Its lead assets include two nab® product candidates—NTB-011, a colchicine-dimer with vascular-disrupting properties, and NTB-010, a geldanomycin-based HSP90 inhibitor—both cleared for IND and slated for Phase I trials in 2014-2015. Beyond nab® molecules, the pipeline features a KRAS inhibitor, p53-remediation compounds, and a library of over 4,000 multi-kinase inhibitors, several of which are expected to enter IND-enabling studies between 2014 and 2016. Founder Dr. Patrick Soon-Shiong reports that more than $100 million has already been invested internally to build this platform. The company’s mission is to deliver “right drug, right time” precision oncology therapies while minimizing side effects through molecularly guided patient selection.

Total raised

$650M

Funding rounds

6

Latest round

Equity

Latest activity

Jul 2015